Corentin grew up near Angouleme, a small town in the south-west of France. He studied chemistry at the University Paris Saclay between the Ecole Normal Superieure de Cachan ( Now ENS Paris Saclay) and the Ecole Polytechnique of Palaiseau near Paris. He obtained his Master in Molecular chemistry after a master thesis on Development and synthesis of metallo-β-lactamases inhibitors under Professor Schofield supervision in Oxford University. He then studied molecular and cellular biology at the  Ecole Polytechnique-Universite Paris Saclay. He was trained in medicinal and biological chemistry under the supervision of Dr. Paola Arimondo and Dr. Ludovic Halby as PhD student at the Institut Pasteur in Paris. He worked on the development of a library of molecules targeted against the methyltransferase family. He designed, synthesized and characterized innovative compounds and participated to their biological evaluation on DNMT and HMT proteins and in cells. He was then awarded in 2021 the Innovation Fellowship of the Novartis Institute for Biomedical Research (NIBR) in Basel mentored by Dr. Alexander Marziale, Dr. Holly Davis and Dr. Fabio Lima. In addition to his part in the MicroCycle platform and in collaborative work with ICIQ, he had the opportunity of creating his own project in chemical biology. 

Outside of the lab, Corentin is enjoying martial arts that he practices for years.

Oxadiazolines as Photoreleasable Labels for Drug Target Identification
C. Bon*, B. Goretzki, M. Flamme, C. Sheldon, H. Davis,
F. Lima, F. Garcia, S. Brittain, C. Brocklehurst
J. Am. Chem. Soc. 2024, 146, 39, 26759–26765.

Identification of a Novel Transasparaginase Activity of Bacillus Subtilis (bTG) for Sequence-Specific Bioconjugation
M. Flamme*, R. Gohring, A. Vissières, C. Bon, J. Voshol, T. Schlama, G. Mann
Bioconjugate Chem.2024, 35, 10, 1512–1523.

MicroCycle: An Integrated and Automated Platform to Accelerate Drug Discovery
C.Brocklehurst*, E. Altmann, C. Bon, H. Davis, D. Dunstan, P. Ertl, C. Ginsburg-Moraff,
J. Grob, D. Gosling, G. Lapointe, A. Marziale, H. Mues, M. Palmieri, R. Robinson,
C. Springer, K. Tan, W. Ullmer, R. Wyler
J. Med. Chem.2024, 67, 3, 2118–2128.

Late-Stage Aryl C-H Bond Cyclopropenylation with Cyclopropenium Cations
H.F. Tu, A. Jeandin, C. Bon, C. Brocklehurst, F.Lima, M.G. Suero*
Angew. Chem. Int. Ed. 2023, 62, 36, e202308379.

Identification of Chemical Probes Targeting MBD2
D. Erdmann, J. Contreras, R. Le Meur, B. Vitorge, V. Saverat, C. Bon,
P. Phansavath, V. Ratovelomanana-Vidal, A. Jeltsch, I. Guijarro, P. B. Arimondo*
ACS Chem. Biol.2022, 17, 6, 1415–1426.

A novel screening strategy to identify histone methyltransferase inhibitors reveals a crosstalk between DOT1L and CARM1
Y. Si, C. Bon, V. Cadet-Daniel, M. Duchateau, M. Matondo, F. Agou, L. Halby, P. B. Arimondo*
RSC Chemical Biology 2022, 3, 456-467.

Quinazoline-Based Analog of Adenine As an Antidote Against MLL-rearranged Leukemia Cells: Synthesis, Inhibition Assays and Docking Studies
C. Bon, Y. Si, C.Jallet, L. Halby and P. B. Arimondo*
Future Medicinal Chemistry 2022, 14 (8), 557–570.

Direct Synthesis of Allyl Amines with 2-Nitrosulfonamide Derivatives via the Tsuji-Trost Reaction
C. Bon, P. B. Arimondo* and L. Halby*
Chemistry Open 2021, 10, 1166–1169.

Synthesis and Biological Activity of a Cytostatic Inhibitor of MLLr Leukemia Targeting the DOT1L Protein
C. Bon, Y. Si, M. Pernak, M. Barchowska, V. Cadet Daniel, A. Tafit, D. Ruzic, N. Djokovic, T. Djikić, K. Nikolic, L. Halby and P. B. Arimondo*
Molecules 2021, 26(17), 5300-5322.

Procainamide-SAHA Fused Inhibitors of hHDAC6 Tackle Multidrug Resistant Malaria Parasites
F. Nardella, L. Halby, I. Dobrescu, J. Viluma, C. Bon, A. Claes, V. Cadet-Daniel, A. Tafit,
C. Roesch, E. Hammam, D. Erdmann, M. Mairet-Khedim, R. Peronet, S. Mecheri, B. Witkowski,
A. Scherf, P. B. Arimondo*
J. Med. Chem.2021, 64, 14, 10403–10417.

Bisubstrate Inhibitors: The Promise of a Selective and Potent Chemical Inhibition of Epigenetic ‘Writers’
C. Bon, L. Halby, P. B. Arimondo*
Epigenomics 2020, 12 (17), 1479-1482.

Targeting DOT1L for Mixed-Lineage Rearranged Leukemia - Chapter 4
C. Bon, Y. Si, P. B. Arimondo*
Histone Modifications in Therapy 2020, 20, 81-99.

A Fluorescence-based Assay for Screening β-Lactams Targeting the Mycobacterium tuberculosis Transpeptidase LdtMt2
M. de Munnik, C. T. Lohans, G. W. Langley, C. Bon, J. Brem, C. J. Schofield*
ChemBioChem 2020, 21(3), 368–372.

 

Chemical Targeting of DNA and Histone Methylation in Cancer: Novelties, Hopes and Promises
C. Bon, D. Erdmann, L. Halby, P. B. Arimondo*
Bulletin du Cancer 2019, 106 (10)823-833.

Structure Activity Relationship Studies on Rhodanines and Derived Enethiol Inhibitors of Metallo-β-Lactamases
D. Zhang M. S.Markoulides D. Stepanovs A. M.Rydzik Ahmed El-Hussein C. Bon, J. Kamps, K. Umlanda, P. M. Collins, S. T. Cahill, D. Y. Wang, F. Von Delft, J. Brem, M. A. Mc.Donough, C. J. Schofield*
Bioorganic medicinal chemistry 2018, 26 (11), 2928-2936.

BF₂-Azadipyrromethene NIR-Emissive Fluorophores with Research and Clinical Potential
H. C. Daly, G. Sampedro, C. Bon, D. Wu, G. Ismail, R. A. Cahill, D. F. O’Shea*
Eur. J. Med. Chem. 2017, 135, 392-400.